Resmetirom is the first FDA-approved drug for NASH with liver fibrosis, offering a new treatment option alongside lifestyle changes. Clinical trials demonstrated significant NASH resolution and ...

VIENNA – Treatment with an investigational FGF21 analogue improved fibrosis in patients with nonalcoholic steatohepatitis (NASH), according to a phase IIb trial. In the ENLIVEN study, patients with ...

Credit: Madrigal Pharmaceuticals. The approval was based on data from the pivotal phase 3 MAESTRO-NASH study, which included patients with biopsy-proven NASH and fibrosis who were on stable doses of ...

Credit: Getty Images. Resmetirom is an oral thyroid hormone receptor-β selective agonist. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ...

Please provide your email address to receive an email when new articles are posted on . Improvement in fibrosis occurred in up to 27% of patients treated with pegozafermin vs. 7% on placebo.

Just as things were getting overheated in the nonalcoholic steatohepatitis (NASH) drug space, GLP-1 receptor agonists showed up to the party with the potential to treat some symptoms of the chronic ...

The oral thyroid hormone receptor beta-selective agonist resmetirom (Madrigal Pharmaceuticals) in both 80-mg and 100-mg doses was superior to placebo at achieving resolution of nonalcoholic ...

VIENNA — A fibroblast growth factor 21 (FGF21) analogue, pegozafermin, significantly improved fibrosis without worsening of nonalcoholic steatohepatitis (NASH) and led to resolution of NASH without ...